Development and preclinical evaluation of tetraspecific antibodies in combination with ex vivo expanded NK cells infusion for improved control of esophageal cancer
Abstract
Abstract Background Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous, leading to limited drug effectiveness and resistance. Antibody therapies offer limited benefits due to low response rates. Multispecific antibodies, targeting multiple tumor antigens and natural killer (NK)-cell receptors, may overcome these challenges, but their effectiveness in ESCC therapy is not yet understood. Methods Transcriptome sequencing and database analysis were performed on samples from patients with ESCC to identify tumor antigens. Multispecific antibodies were designed to target tumor antigens and NK-cell surface markers. Fast protein liquid chromatography and surface plasmon resonance were applied for quality control of antibodies. Using multiple ESCC cell lines and NK cells from different donors, flow cytometry was performed to assess NK cell cytotoxicity and activation. Immunofluorescence assays were used to confirm colocalization. Transcriptome sequencing, flow cytometry and western blots were performed to explore molecular mechanisms. Subcutaneous and metastatic xenograft tumor models were established to evaluate the in vivo antitumor efficacy of antibodies combined with adoptive transfer of NK cells. Results The expression of EGFR was consistently highly expressed in all ESCC samples, while MET was specifically upregulated in recurrent ESCC, whereas the database also validated two antigens overexpression in tumor tissues. Antibodies were successfully engineered for multiple antigens binding. The tetraspecific antibodies significantly enhanced NK-cell cytotoxicity by up to 30% against ESCC and paclitaxel-resistant cell lines compared with the NK-only group in vitro. Transcriptomic analysis and experimental validation revealed that antibodies triggered immune activation pathways and increased the expression of tumor necrosis factor-α, interferon-γ, and granzyme B in NK cells, but also induced NK cell exhaustion. In vivo, tetraspecific antibodies combined with NK cell infusions exerted superior antitumor efficacy, with an 82.3% tumor volume reduction in the early-stage model and 65.7% in the advanced-stage model compared with controls. The therapeutic efficacy was also observed in the metastatic tumor model. Meanwhile, the combination therapy was well tolerated, with enhanced NK cell infiltration in tumor tissues. Conclusions We developed tetraspecific antibodies to effectively bridge ESCC cells and NK cells. The antibodies have the potential to enhance the antitumor activity of NK cells against ESCC. This study supports the clinical translation of tetraspecific antibodies for NK cell-based immunotherapy for ESCC.